In contrast, drugs modeled after gastrointestinal hormones, such as glucagon-like peptide-1 (GLP-1), have been shown to exhibit fewer side effects while demonstrating high efficacy in obesity treatment
Leger, PhD, CDCES, CCRC, and Jean Young Park, MD
The human evidence is still developing
On the access question: We believe patients who have legitimate clinical needs documented injury, inflammatory conditions, immune dysfunction deserve access to evidence-informed therapeutics through licensed, supervised channels
GLP-1s changed everything and WW was standing in the wrong spot when the wave hit
What should I do if I experience urinary incontinence while taking Ozempic